ORDER NOW

Single-site or operational unit license 
$2,500.00 

Global enterprise-wide license PDF:  
$5,000.00 

Country or Global license 
Contact David Cunningham, 
Account Manager, 
781-972-5472 
cunningham@
healthtech.com

Length 
84 pages 

Date published 
September 2006 

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

Comparative Genomic Hybridization: Current State and Future Directions 

Ricki Lewis, PhD 

New Page 1

SECTION 1
CGH Highlights Copy Number Differences

Eclectic Applications
An Overview of the Methodology
The Evolution of CGH

SECTION 2
The Scope of CGH Technology

Methods
Steps
DNA Isolation and Preparation
Amplification
Labeling
Hybridization on a Microarray
Scanning and Analysis
Limitations and Challenges
Underlying Assumptions
Copy Number Polymorphisms (CNPs)
Distinguishing Loss of Heterozygosity
Alternatives to CGH

SECTION 3
Applications of CGH

Reproduction
Assisted Reproduction Technologies
Inherited Developmental Disorders
Mental Retardation
Multifactorial Disorders
Cancer
Evolution

SECTION 4
Expert Interviews

Daniel Pinkel, PhD, University of California, San Francisco,
Comprehensive Cancer Center
Wendy Price, PhD, Invitrogen Corp.
Peggy Eis, NimbleGen Systems Inc.

SECTION 5
Selected Company Profiles

Affymetrix
Agilent
Invitrogen Corp.
Molecular Devices Corp.
NimbleGen Systems Inc.
Signature Genomic Labs, LLC

APPENDIX
CHI Advances: Comparative Genomic Hybridization Survey, August 2006

References

 


About Insight Pharma Reports

How to Order

Journalist Inquiries

Corporate Librarians and Information Services Inquiries

The Insight Pharma Reports Advisory Board

Contact Insight Pharma Reports

 

"CHI's Insight
 Pharma Reports are
 a cost-effective and reliable source
 of information about the markets
 we serve. The cost
 for us to conduct
 this kind of business
 research on our
 own would be
 prohibitive. CHI's
 Insight Pharma
 Reports allow us to
 keep on top of
 developments in
 this rapidly moving
 field." 

--Donald N. Halbert, Ph.D., EVP of R&D, Iconix Biosciences

 

A division of 
Cambridge 
Healthtech Institute


CHI's Insight Pharma Reports, a division of Cambridge Healthtech Institute | 250 First Avenue | Needham, MA 02494
For more information, email Rose LaRaia at rlaraia@healthtech.com or call 781-972-5444